Cadila, India's sixth-largest drugmaker by sales, spent $250...
Cadila, India's sixth-largest drugmaker by sales, spent $250 million developing Lipaglyn, a new chemical entity or new discovery, and aims to spend another $150 million to $200 million to launch the drug outside India.
Click Here or the flag on image above to change the background image


















